# A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

> **NCT05750017** · PHASE1 · UNKNOWN · sponsor: **Beijing Luzhu Biotechnology Co., Ltd.** · enrollment: 66 (estimated)

## Conditions studied

- Herpes Zoster
- Vaccine-Preventable Diseases

## Interventions

- **BIOLOGICAL:** Low Dose Recombinant Herpes Zoster Vaccine (LZ901)
- **BIOLOGICAL:** High Dose Recombinant Herpes Zoster Vaccine (LZ901)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05750017
- **Lead sponsor:** Beijing Luzhu Biotechnology Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-23
- **Primary completion:** 2024-02-01
- **Final completion:** 2024-03-15
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05750017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05750017, "A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05750017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*